Dr.Szu-TahChen Taiwan

Dr.Szu-TahChen
Dr. Szu-Tah Chen is an accomplished endocrinologist specializing in thyroidology, diabetes, and endocrine metabolism. He earned his Bachelor of Medicine from Kaohsiung Medical College and completed postgraduate studies at Chang Gung University of Science and Technology. Dr. Chen underwent residency training in Internal Medicine and fellowship training in Endocrinology and Metabolism at Chang Gung Memorial Hospital (CGMH), Linkou, where he has served since 1990. Over the past three decades, Dr. Chen has made significant contributions to endocrine medicine through clinical service, academic teaching, and research. He was Chief of the Division of Endocrinology and Metabolism at CGMH, Linkou (2014–2020), and led the hospital’s Diabetes Center (2014–2022). Since 2022, he has served as a consultant attending physician at New Taipei Municipal Tucheng Hospital, operated by the Chang Gung Medical Foundation. Concurrently, he holds an academic appointment as Assistant Professor of Medicine at Chang Gung University. Dr. Chen is board-certified in Internal Medicine and in Endocrinology & Metabolism by the Taiwan Society of Internal Medicine and the Endocrine Society of Taiwan. He is an active leader in several professional organizations, including serving as Director of the Endocrinology Society, Pituitary Society, and Taiwan Society of Aldosteronism, as well as Deputy Director of the Taiwan Society of Ultrasound in Medicine. His research focuses on thyroid cancer, diabetes mellitus, and other endocrine disorders. Dr. Chen has published over forty peer-reviewed papers in leading journals such as Clinical and Experimental Metastasis, Scientific Reports, Frontiers in Endocrinology, and the Journal of the Formosan Medical Association. His work has advanced the understanding of endocrine diseases and improved diagnostic and therapeutic strategies for patients in Taiwan and beyond.

21 MARCH

Time Session
13:30
15:00
[Symposium] Pituitary (1)
Consensus in Pituitary Pathology
  • Consensus in Pituitary Pathology: Impact after New Classification for Japan
    Naoko InoshitaJapan Speaker Consensus in Pituitary Pathology: Impact after New Classification for Japan
  • The Impact of the 2022 WHO PitNET Classification to the Clinical Practitioners. Does Silence Equal Acceptance?
    Szu-Tah ChenTaiwan Speaker The Impact of the 2022 WHO PitNET Classification to the Clinical Practitioners. Does Silence Equal Acceptance?The 2022 World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors redefined pituitary adenomas as pituitary neuroendocrine tumors (PitNETs) within the International Classification of Diseases for Oncology, 3rd Edition (ICD-O/3). This change reflects updated insights into tumor biology, recognizing a spectrum of clinical behaviors beyond the traditionally benign designation. A narrative review of the WHO 2022 classification updates was conducted, focusing on their clinical, diagnostic, and epidemiologic implications for practitioners in endocrinology, neurosurgery, and oncology. The reclassification emphasizes the potential for variability in tumor aggressiveness, recurrence, and invasiveness. Clinically, this shift necessitates more careful risk stratification, closer follow-up in selected cases, and a reassessment of treatment algorithms. From a reporting perspective, ICD-O/3 alignment may affect cancer registry data and epidemiologic tracking, altering disease burden estimates. Importantly, the new terminology presents challenges in patient communication, as the label “neuroendocrine tumor” may cause undue anxiety despite the indolent nature of most PitNETs. The WHO 2022 reclassification of pituitary adenomas as PitNETs represents a significant change for clinical practice. While it enhances awareness of potential aggressive behavior, it also requires balanced application in patient care to avoid overtreatment and misperceptions. Practitioners must adapt by refining diagnostic vigilance, tailoring follow-up strategies, and delivering clear patient-centered communication.
  • Consensus in Pituitary Pathology: Impact after New Classification for Korea
    Jae Sung ParkKorea (Republic of) Speaker Consensus in Pituitary Pathology: Impact after New Classification for Korea
201AF